Abcellera Biologics Inc
NASDAQ:ABCL

Watchlist Manager
Abcellera Biologics Inc Logo
Abcellera Biologics Inc
NASDAQ:ABCL
Watchlist
Price: 3.95 USD -2.71%
Market Cap: 1.2B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
-22%
Revenue
Forecast
+7%
Operating Income
Forecast
+16%
Net Income
Forecast
+19%

Wall Street
Price Targets

ABCL Price Targets Summary
Abcellera Biologics Inc

Wall Street analysts forecast ABCL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABCL is 9.33 USD with a low forecast of 5.05 USD and a high forecast of 17.85 USD.

ABCL Lowest Forecast
Wall Street Target
5.05 USD
28% Upside
ABCL Average Forecast
Wall Street Target
9.33 USD
136% Upside
ABCL Highest Forecast
Wall Street Target
17.85 USD
352% Upside
Lowest
Price Target
5.05 USD
28% Upside
Average
Price Target
9.33 USD
136% Upside
Highest
Price Target
17.85 USD
352% Upside
Abcellera Biologics Inc Competitors:
Price Targets
SFZN
Siegfried Holding AG
31% Upside
CRL
Charles River Laboratories International Inc
3% Upside
CDXS
Codexis Inc
153% Upside
BICO
BICO Group AB
76% Upside
SFZN
Siegfried Holding AG
31% Upside
CRL
Charles River Laboratories International Inc
3% Upside
CDXS
Codexis Inc
153% Upside
BICO
BICO Group AB
76% Upside
LONN
Lonza Group AG
17% Upside
BIOT
Biotage AB
3% Upside
BANB
Bachem Holding AG
24% Upside
ADPT
Adaptive Biotechnologies Corp
17% Upside

Revenue
Forecast

Revenue Estimate
Abcellera Biologics Inc

For the last 5 years the compound annual growth rate for Abcellera Biologics Inc's revenue is 20%. The projected CAGR for the next 3 years is 18%.

20%
Past Growth
18%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Abcellera Biologics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Abcellera Biologics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-10%
Average Miss
What are analyst estimates?

See Also

Summary
ABCL intrinsic value, competitors valuation, and company profile.
DCF Valuation
ABCL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ABCL stock valuation using valuation multiples.
Wall Street Estimates
ABCL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ABCL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ABCL's stock price target?
Price Target
9.33 USD

According to Wall Street analysts, the average 1-year price target for ABCL is 9.33 USD with a low forecast of 5.05 USD and a high forecast of 17.85 USD.

What is Abcellera Biologics Inc's Revenue forecast?
Projected CAGR
18%

For the last 5 years the compound annual growth rate for Abcellera Biologics Inc's revenue is 20%. The projected CAGR for the next 3 years is 18%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 268,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.